Public COA audit
Tirzepatide
Audited July 29, 2026
Several fields check out, but we found issues worth reviewing before you rely on this document.
- Legitimacy
- 92
- Confidence
- 93%
- Panels
- 2/7
- Purity (printed)
- 99.8%
Document details
Fields extracted from the certificate — not order or payment data.
- Batch / lot
- MRYVVYD
- Identity method
- FTIR (USP <197A>) and HPLC (USP <621>)
- Sample date
- 2026-04-23
- Issue date
- 2026-04-26
7-panel checklist
Had data + good, had data + bad, reported without pass/fail, or missing. Missing lowers thoroughness — you decide whether that panel matters; PeptIQ’s score still factors coverage.
2 of 7 present · 2 passed · 0 failed · 0 reported · 5 missing
Missing is a thoroughness gap — not automatically bad. PeptIQ’s legitimacy score still weighs panel coverage; you can down-weight panels that don’t matter for your use case.
Identity
Tested · passed · core
Compound identity confirmed (e.g. HPLC, mass spec).
FTIR sample spectrum confirms the presence of Tirzepatide with addition of excipient(s)/fillers
Purity
Tested · passed · core
Reported purity percentage for the analyte.
99.8%
Heavy metals
Not on this COA
Lead, arsenic, cadmium, mercury, or similar limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Microbial
Not on this COA
Bioburden / microbial limits testing.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Endotoxin
Not on this COA · core
LAL or chromogenic endotoxin assay.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Sterility
Not on this COA
Sterility testing where applicable.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
Residual solvent / water
Not on this COA
Residual solvents or water content limits.
No evidence for this panel. That lowers thoroughness — whether it matters depends on what you care about.
How to read this
Had data · good
Panel present with a pass (or clear acceptance).
Had data · bad
Panel present with a fail — a concrete quality signal.
Had data · unclear
Value reported without an explicit pass/fail mark.
Missing
Not on this certificate. Lowers thoroughness; you decide if that panel matters for your use case. PeptIQ’s score still factors coverage.
Findings
Evidence-linked observations from this audit.
High HPLC purity confirmed
99.8% purity by HPLC (USP <621>) meets specification of ≥98%. This is normal for research-grade peptides.
Identity confirmed by FTIR and HPLC
FTIR spectrum confirms Tirzepatide presence with excipients. HPLC chromatogram shows single major peak at 10.713 min retention time.
Batch/lot number clearly stated
Lot MRYVVYD with BT Sample ID 005000039746020
Testing and issue dates present and reasonable
Tested 2026-04-23, issued 2026-04-26 (3-day turnaround)
Testing lab identified with contact information
BTLabs, West Palm Beach FL, with phone, email, and website. Digital signatures from two scientists (Andrea Castro, AS and Verna Zheng, AS).
Limited testing scope
COA explicitly states it does not provide information on particulate matter, microbial contamination, or endotoxins. Only identity, purity, and potency tested. This is disclosed and not uncommon for basic peptide analysis.
Professional formatting with supporting data
Includes FTIR spectrum and HPLC chromatogram on page 2. USP method references provided. Peptide-to-excipient ratio calculated (1:4.8).
Third-party verification URL provided
Finnrick provides verification at https://finnrick.com/verify with certificate ID mryvvyd
PeptIQ COA reports analyze document content and publicly verifiable lab signals. They are educational and not a guarantee of product quality, legality, or safety. Always consult a qualified professional before making health decisions. We never publish purchase prices, shipping details, or uploader identity.